.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

SVR Achieved With 8-Week Course in Coinfected Hepatitis C Patients

Published on: May 22, 2015

Encouraging results with a shorter course of hepatitis C treatment were presented at the Digestive Disease Week meeting. Patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naÃ¯ve to direct-acting antiviral treatment, achieved a sustained response at 12 weeks.

Results, presented at the Digestive Disease Week meeting, from HIV-coinfected hepatitis C virus (HCV) patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment., were encouraging The data showed that once-daily daclatasvir combined with sofosbuvir, administered for 8 weeks, achieved a sustained virologic response in more than 75% of patients, 12 weeks after finishing the course.

While the treatment was well-tolerated overall, post-treatment hepatitis C virus relapse occurred in 1% to 2% of patients in the 12-week treatment groups and in about 25% in the 8-week group.

Read the complete article on MedPage Today: http://bit.ly/1c94yhg